Since their development, induced pluripotent stem cells (iPSCs) have become an increasingly useful tool in drug discovery. However, accessing clinical material from the relevant patient population can prove challenging. If you cannot locate human tissue for reprogramming, we can ethically source fresh clinical material for you through our global procurement network.
1. Patient Recruitment – with over 25 years of experience in the biobank sector, REPROCELL operates an extensive human tissue network. Through our clinical partnerships, we can access a diverse range of donors with a full-medical and drug history.
2. Next-Generation Sequencing – screening for donors who meet your genetic criteria is achieved via our broad portfolio of Next Generation Sequencing (NGS) services. This includes, but is not limited to, whole genomic and exome sequencing plus targeted region sequencing. With these advanced screening techniques, we can access donors who can fulfill your specific research needs. You can read more about our NGS capabilities in our online portfolio.
3. Dynamic Reprogramming – our laboratory team are available 24 hours a day to collect fresh tissue samples once they are made available. With REPROCELL’s latest-generation reprogramming technology, our scientists can derive human iPSCs from fibroblasts, blood, and even urine to fulfill your unique research needs.
REPROCELL’s unique Alzheimer’s disease (AD) model was established from relevant donor fibroblasts. Through our clinical partnerships, patients with AD were identified. After obtaining informed consent, donor blood samples were then screened for the R62H mutant variant of the Presenilin 2 (PS2) gene and fibroblasts were collected from the relevant patient. Following reprogramming, these iPSCs were subsequently differentiated into neurons and then expanded and characterized (Figure 1).
Stem Cell Services
Zara Puckrin, BSc / 2 July 2021
Zara Puckrin, BSc / 8 June 2021
Zara Puckrin, BSc / 31 May 2021
© 2021 REPROCELL Inc. All rights reserved.